1. Home
  2. Live Updates
  3. 2 deoxyd glucose

Live Breaking News & Updates on 2 deoxyd glucose

Stay informed with the latest breaking news from 2 deoxyd glucose on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in 2 deoxyd glucose and stay connected to the pulse of your community

DRDO invites EoI to transfer technology of 2-DG drug for bulk production

The 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr. Reddy’s Laboratories.

Technical-assessment-committee , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , Active-pharmaceutical-ingredient , Drug-licensing-authorities , Defence-research-and-development-organisation , Drdo , 2-dg

Coronavirus | 2-DG Anti Covid Drug: DRDO launches anti-COVID medicine, 2-deoxy-D-glucose, know all about how it works


facebook
Pintrest
The DRDO's (Defence Research and Development Organisation) newly launched anti-COVID medicine, 2-deoxy-D-glucose is being hailed as an innovative holy grail for COVID patients in India right now, who are currently battling for their lives and scouring for oxygen amidst a deadly grasp of the second wave of infections.
The innovative therapeutic drug, which has been launched for use today (May 17) is also said to hasten recovery timelines. But how effective is it really? Can all COVID-19 patients take it? Here's a brief explainer on the same.
What do we know about the drug, 2-deoxy-D-glucose?
2-deoxy-D-glucose is the first-ever 'fully homegrown' anti-COVID medicine which has been developed in India. According to researchers, it is one of the first therapeutic COVID-19 drugs which works to stop viral growth in the body, reduce the need for external oxygen.

Delhi , India , Hyderabad , Andhra-pradesh , Telangana , Development-organisation , Institute-of-nuclear-medicine , Defence-research , Nuclear-medicine , Allied-sciences , Drugs-controller-general

DRDO's anti-Covid drug released - The Hindu BusinessLine


May 17, 2021
Union Defence Minister Rajnath Singh hands over anti-Covid drug 2-DG to Health Minister Harsh Vardhan   -  PTI
Union Defence Minister Rajnath Singh hands over anti-Covid drug 2-DG to Health Minister Harsh Vardhan   -  PTI×
First batch of 2-DG dedicated to nation
The first batch of the anti-Covid drug 2-DG (2-deoxy-D-glucose), developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) scientists jointly with their counterparts at Dr Reddy’s Laboratories in Hyderabad, was dedicated to the nation by Defence Minister Rajnath Singh on Monday.
The INMAS, a lab under the Defence Research and Development Organisation, had developed the molecule for treating cancer, but it has not been repurposed for treating Covid-19 infection as adjuvant as well as standalone medication.

India , Hyderabad , Andhra-pradesh , Harsh-vardhan , Randeep-guleria , V-satish-reddy , Dr-reddy-lab , Armed-forces-medical-services , Institute-of-nuclear-medicine , Development-organisation , India-institute-of-medical-sciences , Defence-research

Govt. releases DRDO's COVID drug for emergency use


Updated:
Developed with DRL, it reduces oxygen-dependence in patients
Share Article
AAA
Defence Minister Rajnath Singh hands over the first batch of 2-DG anti Covid drug to the Union Health Minister Harsh Vardhan, in New Delhi on May 17, 2021. Photo: Twitter/@rajnathsingh
 
Developed with DRL, it reduces oxygen-dependence in patients
The first batch of the adjunct COVID therapy drug, 2-deoxy-D-glucose (2-DG) — developed by the Defence Research and Development Organisation (DRDO) along with Dr Reddy’s Laboratories (DRL), Hyderabad — was on Monday released for emergency use. Defence Minister Rajnath Singh formally handed over the drug to Health Minister Dr Harsh Vardhan.
“One box each of the sachets of the drug were handed over to Dr. Randeep Guleria, Director All India Institute of Medical Sciences (AIIMS) and Lt. Gen. Sunil Kant of Armed Forces Medical Services (AFMS). More will be handed over to different hospitals across the country for emergency use,” a Defence Ministry statement said.

Uttar-pradesh , India , Karnataka , Delhi , Hyderabad , Andhra-pradesh , Telangana , Tamil-nadu , Harsh-vardhan , Rajnath-singh , G-satheesh-reddy , Sunil-kant

What is 2-DG: Crucial Information Missing About DRDO's Anti-COVID Drug Approved for Emergency Use

2-DG 's therapeutic use for COVID-19 is set to begin in the coming week. However, there are several gaps in the information surrounding the drug trials and a lack of available data.

India , Dg-ministry-of-defence-press-information-bureau , Central-drugs-standard-control-organization , Ministry-of-defence , Defence-research , Centre-for-cellular , Ministry-of-defence-press-information-bureau , Development-organisation , Institute-of-nuclear-medicine , Drugs-controller-general , Nuclear-medicine

First batch of DRDO's anti-Covid drug to be released on Monday | India News

India News: NEW DELHI: The first batch of anti-COVID drug 2-DG, developed by the DRDO, will be released on Monday by defence minister Rajnath Singh and health min.

Hyderabad , Andhra-pradesh , India , Harsh-vardhan , Rajnath-singh , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Drugs-controller-general , Nuclear-medicine , Allied-sciences , Ndia-news

Dr Reddy's Q4 net down 28% at ₹554 cr - The Hindu BusinessLine

Pharma major Dr Reddy’s Laboratories Ltd net profit decreased 28 per cent at ₹554 crore in the fourth quarter ended March 31, 2021 as against ₹764 crore in the corresponding quarter of the previous

United-states , Hyderabad , Andhra-pradesh , India , America , Avigan-favipiravir , Dr-reddy-laboratories-ltd , Laboratories-ltd , North-america , Dr-reddy-39-s , Sputnik , Vaccine

2-deoxy-D-glucose: DRDO's anti-COVID-19 drug is safe, will help patients recover faster, says INMAS scientist


Source:
ANI
New Delhi: Dr Sudhir Chandna, Institute of Nuclear Medicine and Allied Sciences (INMAS) scientist has said the recently approved anti-COVID-19 drug 2-deoxy-D-glucose (2-DG) is completely safe and will help patients recover faster.
"During clinical trials, it has yielded an effective result in curing patients infected with COVID-19. The medicine has gone through clinical trials on around 110 patients in the second phase. In the third phase, it was tried on 220 patients. It has shown better efficacy in phase two itself as compared to the standard care," Dr Chandna said.
"Recovery was two to three days faster for COVID-19 patients," he added.

Hyderabad , Andhra-pradesh , India , New-delhi , Delhi , Sudhir-chandna , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , 2-deoxyd-glucose

EXCLUSIVE: DRDO's anti-Covid oral drug to roll out by May 11


URL copied
DRDO's anti-Covid oral drug to roll out by May 11
In an exclusive conversation with India TV, DRDO chief G. Satheesh Reddy on Sunday said the anti-COVID drug, which has been approved for emergency use, will be rolled out by May 11. Explaining further, the DRDO chief said the drug will help neutralise most of the COVID-19 symptoms and will prevent the growth of the virus inside the body. Regarding the availability of the drug, Reddy said arrangements for proper distribution across all hospitals need to be done and a team is already working on the same. 
Speaking about the drug, the DRDO chief also said it would help improve the level of oxygen in the body. The drug is expected to help coronavirus patients within three days of consumption. 

India , Hyderabad , Andhra-pradesh , G-satheesh-reddy , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Image-source , Nuclear-medicine , Allied-sciences , Drugs-controller-general